Dapagliflozin Gets Expanded Heart Failure Indication in Europe Dapagliflozin Gets Expanded Heart Failure Indication in Europe

The European Commission has expanded the indication of the SGLT2 inhibitor to include HF with mildly reduced and preserved ejection fraction, based on the DELIVER phase 3 trial.International Approvals

Source: Medscape Cardiology Headlines - February 9, 2023 Category: Cardiology Tags: Cardiology News Source Type: news